CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Gefapixant 45 mg +1 moredrug
Likely dose
Gefapixant 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482713
NCT03482713Phase 2Completed
CompareCT.gov

Phase II Study, Randomized, Double-Blind, Placebo-Controlled 4-Week Clinical Study, to Evaluate the Efficacy and Safety of MK-7264 in Adult Japanese Participants With Unexplained or Refractory Chronic Cough

Merck Sharp & Dohme LLC·interventional·Posted Mar 29, 2018·Updated Oct 17, 2019

In Brief

A Phase 2 clinical trial evaluating Gefapixant 45 mg and Placebo for Chronic Cough. Completed, enrolled 23 participants across 16 sites.

Detailed Summary

This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cough
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMar 16, 2018
Primary CompletionJun 7, 2018
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.3 years ago

Interventions

Gefapixant 45 mgdrug

Gefapixant 45 mg (film-coated tablet) to be administered orally BID

Placebodrug

Placebo (film-coated tablet) matching gefapixant to be administered orally BID